Nitric oxide and atherosclerosis

Nitric Oxide - Biology and Chemistry

Volumn 5, Issue 2, 2001, Pages 88-97

  Napoli, Claudio ^a   Ignarro, Louis J ^b  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Atherosclerosis; Coronary heart disease; Nitric oxide; Nitric oxide synthase; Page paragraph line

Indexed keywords

NITRIC OXIDE; NITRIC OXIDE SYNTHASE;

ATHEROGENESIS; ATHEROSCLEROSIS; ENZYME INDUCTION; HUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SHORT SURVEY; SIGNAL TRANSDUCTION;

EID: 0035705616     PISSN: 10898603     EISSN: None     Source Type: Journal    
DOI: 10.1006/niox.2001.0337     Document Type: Article

References (70)

1. Nitric oxide as a signaling molecule in the vascular system: An overview
2. Systemic nature of endothelial dysfunction in atherosclerosis
3. Nitric oxide and coronary endothelial dysfunction in humans
4. Is atherosclerosis an arginine deficiency disease?
5. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries
6. Endothelial dysfunction of coronary microvasculature is associated with impaired coronary blood flow regulation in patient with early atherosclerosis
7. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia
8. Investigation of decreased availability of nitric oxide precursor as a mechanism responsible for impaired endothelium dependent vasodilation in hypercholesterolemic patients
9. Impaired vasodilation of forearm resistance vessels in hypercholesterolemic humans
10. Hypercholesterolemia increases in endothelial superoxide anion production
11. Basal and flow-mediated nitric oxide production by atheromatous coronary arteries
12. Inducible NO synthase is present within human atherosclerotic lesions and promotes the formation and activity of peroxynitrite
13. L-arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans
14. Correction of endothelial dysfunction in coronary microcirculation of hypercholesterolemic patients by L-arginine
15. Coronary stenosis dilation induced by L-arginine
16. Long-term L-arginine supplementation improves small-vessel coronary endothelial function in humans
17. Effects of changing the availability of the substrate for nitric oxide synthase by L-arginine administration on coronary vasomotor tone in angina patients with angiographically narrowed and in patients with normal coronary arteries
18. Clinical and inflammatory effects of dietary L-arginine in patients with intractable angina pectoris
19. Effect of L-arginine administration on myocardial thallium-201 perfusion during exercise in patients with angina pectoris and normal coronary angiograms
20. Oral L-arginine in patients with coronary artery disease on medical management
21. Endogenous nitric oxide synthase inhibitor: A novel marker of atherosclerosis
22. Gene transfer of nitric oxide synthase: Effects on endothelial biology
23. Ex vivo gene transfer of endothelial nitric oxide synthase to atherosclerotic rabbit aortic rings improves relaxations to acetylcholine
24. Distribution and prevalence of inducible nitric oxide synthase in atherosclerotic vessels of long-term cholesterol-fed rabbit
25. Regression of atherosclerosis: Role of nitric oxide and apoptosis
26. Role of endogenous nitric oxide in progression of atherosclerosis in apolipoprotein E-deficient mice
27. Expression of inducible nitric oxide synthase in macrophages and smooth muscle cells in various types of human atherosclerotic lesions
28. Atherosclerosis - An inflammatory disease
29. Cyclooxygenase-2 is widely expressed in atherosclerotic lesion affecting native and transplanted human coronary arteries and colocalizes with inducible nitric oxide synthase and nitrotyrosine particularly in macrophages
30. Expression of interleukin-10 in advanced human atherosclerotic plaques: Relation to inducible nitric oxide synthase expression and cell death
31. A common variant of the endothelial nitric oxide synthase (Glu298 → Asp) is a major risk factor for coronary artery disease in the UK
32. Methylene tetrahydrofolate reductase (MTHFR) and nitric oxide synthase (ecNOS) genes and risks of peripheral arterial disease and coronary heart disease: Edinburgh artery study
33. Atherogenic lipids and endothelial dysfunction: Mechanisms in the genesis of ischemic syndromes
34. The oxidation hypothesis of atherosclerosis
35. Oxidized lipoproteins and nitric oxide
36. Fatty streak formation occurs in human fetal aortas and is greatly enhanced by maternal hypercholesterolemia. Intimal accumulation of low density lipoprotein and its oxidation precede monocyte recruitment into early atherosclerotic lesions
37. Intracranial arteries of human fetuses are more resistant to hypercholesterolemia-induced fatty streak formation than extracranial arteries
38. Influence of maternal hypercholesterolemia during pregnancy on progression of early atherosclerotic lesions in childhood: Fate of Early Lesions in Children (FELIC) study
39. Impairment of endothelim-dependent arterial relaxation by lysolecithin in modified low-density lipoproteins
40. Native and oxidized low-density lipoproteins have different inhibitory effects on endothelium-derived relaxing factor in the rabbit aorta
41. Oxidized low density lipoproteins cause contraction and inhibit endothelium-dependent relaxation in the pig coronary artery
42. Oxidized low density lipoproteins inhibits relaxations of porcine coronary arteries: Role of scavenger receptor and endothelium-derived nitric oxide
43. The effects of native and oxidized low-density lipoproteins on the formation and inactivation of endothelium-derived relaxing factor
44. Atherosclerosis or lipoprotein-induced endothelial dysfunction
45. Inactivation of endothelial derived relaxing factor by oxidized lipoproteins
46. Oxidation of LDL by myeloperoxidase and reactive nitrogen species: Reaction pathways and antioxidant protection
47. Modulation by α- and γ-tocopherol of apoptotic signaling induced by oxidized low-density lipoprotein in human coronary smooth muscle cells
48. Mildly oxidized low-density lipoprotein activates multiple apoptotic signaling pathways in human coronary cells
49. Native low-density lipoprotein increases endothelial cell nitric oxide synthase generation of superoxide anion
50. Effect of native and oxidized low-density lipoprotein on endothelial nitric oxide and superoxide production: Key role of L-arginine availability
51. Mildly oxidized low-density lipoprotein impairs responses of carotid but not basilar artery in rabbits
52. Inhibitory effect of inducible type nitric oxide synthase on oxidative modification of low density lipoprotein by vascular smooth muscle cells
53. Mildly oxidized LDL induces platelet aggregation through activation of phospholipase A2
54. Enhancement by glucose of low density lipoprotein-oxidation by peroxynitrite
55. NO-aspirins, a class of new-inflammatory and anti-thrombotic agents
56. High density lipoprotein prevents oxidized low density lipoprotein-induced inhibition of endothelial nitric-oxide synthase localization and activation in caveolae
57. Novel mechanism for endothelial dysfunction: Dysregulation of dimethylarginine dimethylaminohydrolase
58. LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells: Involvement of S-Adenosylmethionine-dependent methyltransferases
59. On the role of vitamin C and other antioxidants in atherogenesis and vascular dysfunction
60. Nitric oxide in endothelial dysfunction and vascular remodeling: Clinical correlates and experimental links
61. Dietary L-arginine and alpha-tocopherol reduce vascular oxidative stress and preserve endothelial function in hypercholesterolemic rabbits via different mechanisms
62. Plasma alpha-tocopherol and coronary endothelium-dependent vasodilator function
63. Dietary supplementary with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: Results of the GISSI-Prevenzione Trial
64. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients
65. Vitamin E and heart disease: Basic science to clinical intervention trials
66. Lipid peroxidation, antioxidants and cardiovascular disease: How should we move forward?
67. Is there a potential therapeutic role for vitamin E or other antioxidants in atherosclerosis?
68. Design of Physicians' Health Study II - A randomized trial of beta-carotene, vitamins E and C, and multivitamins, in prevention of cancer, cardiovascular disease, and eye disease, and review of results of completed trials
69. Vitamin E and vascular homeostasis: Implications for atherosclerosis
70. Antioxidants and the bioactivity of endothelium-derived nitric oxide